<DOC>
	<DOCNO>NCT00517387</DOCNO>
	<brief_summary>Recently publish work examine effect `` atypical antipsychotic '' SSRI-treatment resistant patient . In study , patient unipolar depression treat SSRI 's , responsive treatment 4 week , supplement atypical . The atypical antipsychotic find diminish depression symptom , well benefit sleep quality . We propose similar study Quetiapine XR , focus thinking process , mood anxiety . Patients depression SSRI treatment resistant treat Quetiapine . Cognition evaluate UBC Mood Disorders Clinic two time : first Quetiapine addition , 8 week . Depression symptoms measurement do 9 time point : Quetiapine , week treatment begin . The primary purpose study evaluate superiority Quetiapine XR compare placebo augmentation therapy treatment anxiety depressive symptom SSRI-nonresponsive unipolar patient . Secondarily , would like evaluate safety tolerability quetiapine augmentation therapy SSRI-nonresponsive unipolar patient .</brief_summary>
	<brief_title>The Effects Quetiapine XR Cognition , Mood Anxiety Symptoms SSRI-Resistant Unipolar Depression</brief_title>
	<detailed_description>This double-blind , placebo-controlled study , patient receive treatment Quetiapine XR 8 week . All patient receive Quetiapine XR initial dose 50mg/day increase incrementally ( dose 50mg/day 2 150mg/day 3 ) achieve target dose 300 mg/day day 4 . Tablets self-administered early night . Patient 's result compare baseline measurement , double-blind fashion . Recruited patient evaluate nine time point : baseline prior treatment ( = -7 day ) , assessment one week treatment begin ( = 7 day ) , two week ( = 14 day ) , three week ( = 21 day ) , four week ( = 28 day ) , five week ( = 35 day ) , six week ( = 42 day ) , seven week ( = 49 day ) 8 week treatment ( = 56 day ) . Evaluation cognition , mood anxiety , do blind time point measure . Basic blood work ( fast blood glucose , lipid screen include triglyceride , urea electrolyte , cytokine neuroimmune marker ) perform patient baseline ( = -7 day ) = 56 day . At 4 week , blood sample take fast plasma glucose , HbA1c transaminases . At baseline ( -7 day ) completion ( 56 day ) battery neurocognitive-impairment test ( see Appendix A ) administer . In addition , Hamilton Rating Scale Depression ( 21-ITEM HAM-D GRID ) , Montgomery -Asberg Depression Rating Scale ( MADRS ) , Hamilton Ratings Scale Anxiety ( HAM-A ) , UKU Side Effect Rating Scale , Quality Life Enjoyment Satisfaction Questionnaire ( Q-LES-Q ) also assess research team .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Provision write informed consent 2 . A diagnosis Unipolar Depression Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIVTR ) 3 . Females male age 1965 year 4 . Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrolment 5 . Able understand comply requirement study 6 . Minimum 21item HAMD GRID score 15 7 . Prior treatment therapeutic dos SSRItype antidepressant least 6 week 8 . Unsatisfactory response treatment , determine clinician , least 6 week . 1 . Pregnancy lactation 2 . Any DSMIV Axis I disorder define inclusion criterion 3 . English second language 4 . Patients , opinion investigator , pose imminent risk suicide danger self others 5 . Known intolerance lack response quetiapine fumarate , judge investigator 6 . Use follow cytochrome P450 3A4 inhibitor 14 day precede enrolment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir 7 . Use follow cytochrome P450 inducer 14 day precede enrollment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoids 8 . Administration depot antipsychotic injection within one dose interval ( depot ) randomisation 9 . Substance alcohol dependence enrolment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion 10 . Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within 4 week prior enrolment 11 . Medical condition would affect absorption , distribution , metabolism , excretion study treatment 12 . Unstable inadequately treat medical illness ( e.g . diabetes , angina pectoris , hypertension ) judge investigator 13 . Involvement plan conduct study 14 . Previous enrolment randomisation treatment present study . 15 . Participation another drug trial within 4 week prior enrolment study long accordance local requirement 16 . Previous head injury , associate loss consciousness . 17 . Neurological disorder . 18 . Significant physical health problem 19 . An absolute neutrophil count ( ANC ) 1.5 x 109 per liter ; 20 . A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrollment glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % . Admitted hospital treatment DM DM relate illness past 12 week . Not physician care DM Physician responsible patient 's DM care indicate patient 's DM control . Physician responsible patient 's DM care approve patient 's participation study . Has dose oral hypoglycaemic drug ( ) and/or diet 4 week prior randomization . For thiazolidinediones ( glitazones ) period le 8 Weeks . Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week Note : If diabetic patient meet one criterion , patient exclude even treat physician believe patient stable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Depression</keyword>
	<keyword>SSRI</keyword>
	<keyword>Atypical Antipsychotic</keyword>
	<keyword>Cognition</keyword>
	<keyword>Mood</keyword>
	<keyword>Quality Life</keyword>
</DOC>